Chemoinformaics analysis of 2-(4-Methoxyphenyl)-3-methyloxirane
| Molecular Weight | 164.204 | nRot | 2 |
| Heavy Atom Molecular Weight | 152.108 | nRig | 9 |
| Exact Molecular Weight | 164.084 | nRing | 2 |
| Solubility: LogS | -2.982 | nHRing | 1 |
| Solubility: LogP | 2.339 | No. of Aliphatic Rings | 1 |
| Acid Count | 0 | No. of Aromatic Rings | 1 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 24 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 12 | No. of Aromatic Carbocycles | 1 |
| nHetero | 2 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 12 | No. of Saturated Hetero Cycles | 1 |
| No. of Carbon atom | 10 | No. of Saturated Rings | 1 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 6 |
| No. of Oxygen atom | 2 | No. of Arom Bond | 6 |
| nHA | 2 | APOL | 26.3055 |
| nHD | 0 | BPOL | 15.5105 |
| QED | 0.625 |
| Synth | 2.499 |
| Natural Product Likeliness | 0.766 |
| NR-PPAR-gamma | 0.002 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0.001 |
| Pgp-sub | 0.001 |
| HIA | 0.003 |
| CACO-2 | -4.464 |
| MDCK | 0.0000217 |
| BBB | 0.79 |
| PPB | 0.712742 |
| VDSS | 1.309 |
| FU | 0.187204 |
| CYP1A2-inh | 0.431 |
| CYP1A2-sub | 0.935 |
| CYP2c19-inh | 0.66 |
| CYP2c19-sub | 0.859 |
| CYP2c9-inh | 0.182 |
| CYP2c9-sub | 0.822 |
| CYP2d6-inh | 0.112 |
| CYP2d6-sub | 0.902 |
| CYP3a4-inh | 0.113 |
| CYP3a4-sub | 0.446 |
| CL | 10.066 |
| T12 | 0.2 |
| hERG | 0.024 |
| Ames | 0.735 |
| ROA | 0.1 |
| SkinSen | 0.197 |
| Carcinogencity | 0.732 |
| EI | 0.901 |
| Respiratory | 0.343 |
| NR-Aromatase | 0.01 |
| Antiviral | No |
| Prediction | 0.892178 |